A
Akhil Chopra
Researcher at Johns Hopkins University
Publications - 29
Citations - 3901
Akhil Chopra is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Nivolumab & Sorafenib. The author has an hindex of 12, co-authored 29 publications receiving 2765 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae You Kim,Su Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani,Ignacio Melero +20 more
TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.
Journal ArticleDOI
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
Brigette B.Y. Ma,Wan-Teck Lim,Boon Cher Goh,Edwin P. Hui,Kwok Wai Lo,Adam Pettinger,Nathan R. Foster,Jonathan W. Riess,Mark Agulnik,Alex Y. Chang,Akhil Chopra,Julie A. Kish,Christine H. Chung,Douglas Adkins,Kevin J. Cullen,Barbara J. Gitlitz,D. Lim,Ka Fai To,K.C. Allen Chan,Y.M. Dennis Lo,Ann D. King,Charles Erlichman,Jun Yin,Brian A. Costello,Anthony T.C. Chan +24 more
TL;DR: Nivolumab has promising activity in NPC and the 1-year overall survival rate compares favorably with historic data in similar populations and the biomarker results were hypothesis generating and validation in larger cohorts is needed.
Journal ArticleDOI
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
Anthony B. El-Khoueiry,Ignacio Melero,Todd S. Crocenzi,Theodore H. Welling,Thomas Yau,Winnie Yeo,Akhil Chopra,Joseph F. Grosso,Lixin Lang,Jeffrey Anderson,Christine Dela Cruz,Bruno Sangro +11 more
TL;DR: Nivolumab has a manageable AE profile and produced durable responses across all dose levels and HCC cohorts, with a favorable 6-month OS rate.
Journal ArticleDOI
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
Thomas Yau,Chiun Hsu,Tae You Kim,Su Pin Choo,Yoon-Koo Kang,Ming-Mo Hou,Kazushi Numata,Winnie Yeo,Akhil Chopra,Masafumi Ikeda,Ryoko Kuromatsu,Michihisa Moriguchi,Yee Chao,Huanyu Zhao,Jeffrey Anderson,Christine Dela Cruz,Masatoshi Kudo +16 more
TL;DR: The CheckMate 040 study as mentioned in this paper evaluated the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma who were refractory to previous sorafenib treatment or chemotherapy.
Journal ArticleDOI
Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
Todd S. Crocenzi,Anthony B. El-Khoueiry,Thomas Yau,Ignacio Melero,Bruno Sangro,Masatoshi Kudo,Chiun Hsu,Jörg Trojan,Tae-You Kim,Su Pin Choo,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Adyb Baakili,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Theodore H. Welling +18 more
TL;DR: Nivo is a fully human anti–PD-1 IgG4 mAb that demonstrated durable responses in patients with advanced HCC on SOC therapy and was approved by the European Medicines Agency (EMA) as well as the US Food and Drug Administration (FDA) for similar reasons.